

References

I-94

1. Virgili G, Parravano M, Menchini F, et al. Anti-vascular endothelial growth factor for diabetic macular oedema. *Cochrane Database Syst Rev*. 2014;10:CD007419.
2. The Diabetic Retinopathy Clinical Research N. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema. *N Engl J Med*. 2015;372(13):1193-1203.
3. Ip MS, Domalpally A, Sun JK, et al. Long-term Effects of Therapy with Ranibizumab on Diabetic Retinopathy Severity and Baseline Risk Factors for Worsening Retinopathy. *Ophthalmology*. 2015;122(2):367-374.
4. Andreoli MT, Pinnolis M, Kieser T, Sun J, Andreoli CM. Feasibility and efficacy of a mass switch from ranibizumab (Lucentis) to bevacizumab (Avastin) for treatment of neovascular age-related macular degeneration. *Journal of Ophthalmology*. 2015;29-34.
5. Heier JS, Bressler NM, Avery RL, et al. Comparison of Aflibercept, Bevacizumab, and Ranibizumab for Treatment of Diabetic Macular Edema. *JAMA Ophthalmol*. 2016;134(1):95–99.
6. The Diabetic Retinopathy Clinical Research Network. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema. *N Engl J Med*. 2015; 372:1193-1203.
7. Li E, Greenberg PB, Voruganti I, Krzystolik G. Cost and Selection of Ophthalmic Anti-Vascular Endothelial Growth Factor Agents. *Rhode Island Medical Journal*. 2016;15-16.
8. EYLEA® (aflibercept) [package insert]. Tarrytown, NY. Regeneron Pharmaceuticals, Inc.: 2011, revised 08/2019.
9. MACUGEN® (pegaptanib sodium injection) [package insert]. Bridgewater, NJ. Bausch + Lomb Inc.: 2004, revised 07/2016.
10. LUCENTIS® (ranibizumab injection) [package insert]. South San Francisco, CA. Genentech, Inc: 2006, revised 03/2018.
11. JETREA® (ocriplasmin) [package insert]. Iselin, NJ. ThromboGenics, Inc.: 2012, revised 02/2017.
12. AVASTIN (bevacizumab) [package insert]. South San Francisco, CA. Genentech, Inc.: 2004, revised 06/2019.
13. Clinical Pharmacology Compendia. [database online]. 2019. Tampa FL: Gold Standard, Inc. aflibercept.
14. Clinical Pharmacology Compendia. [database online]. 2019. Tampa FL: Gold Standard, Inc. pegaptanib sodium.
15. Clinical Pharmacology Compendia. [database online]. 2019. Tampa FL: Gold Standard, Inc. ranibizumab injection.
16. Clinical Pharmacology Compendia. [database online]. 2019. Tampa FL: Gold Standard, Inc. ocriplasmin.
17. Clinical Pharmacology Compendia. [database online]. 2019. Tampa FL: Gold Standard, Inc. bevacizumab.
18. Writing Committee for the Diabetic Retinopathy Clinical Research Network. Panretinal photocoagulation vs intravitreal ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial. *JAMA*. 2015;314(20):2137-2146.

19. Clinical Pharmacology Compendia. [database online]. 2019. Tampa FL: Gold Standard, Inc. Brolucizumab-dbl.
20. Beovu® (brolucizumab-dbl) injection [package insert]. East Hanover, NJ. Novartis Pharmaceuticals Corp.: Approved 10/2019.
21. Micromedex®Solutions Compendia. 2019. Bevacizumab.
22. Dugel P, Koh A, Ogura Y, et al. HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. *Ophthalmology*. 2020;127:72-84.
23. Cheung C, Arnold J, Holz F, et al. Myopic Choroidal Neovascularization: Review, Guidance, and Consensus Statement on Management. *Ophthalmology*. 2017;124:1690-1711.
24. Micromedex®Solutions Compendia. 2019. Brolucizumab.
25. Micromedex®Solutions Compendia. 2019. Ranibizumab.
26. Micromedex®Solutions Compendia. 2019. Pegaptanib.
27. Micromedex®Solutions Compendia. 2019. Aflibercept.
28. Micromedex®Solutions Compendia. 2019. Ocriplasmin.